Medical Information
Week ending August 28, 2026
1. This week’s recurring question themes
Baseline week: 9 distinct questions and 63 responses; each question received 7 answer variants.
- Administration, dosing, and handling — ~4 questions/28 responses:
“How should I apply Valchlor—how much to use, and should I cover the area with a bandage?”; “What’s the recommended dosing schedule… and how many weeks”; accidental eye/mouth exposure; and use on “broken, infected, or oozing” skin or active eczema. - Comparisons and treatment selection — 3 questions/21 responses:
Differences in “strength, formulation, or how you apply it”; switching to another topical therapy; and whether Valchlor is “stronger” than other topicals. - Off-label use — 1 question/7 responses:
“I have molluscum contagiosum on my wrist—can I use Valchlor for that?” - Named alternative comparison — 1 question/7 responses:
“Valchlor vs imiquimod”—purpose and reasons to choose one over the other.
2. Where no consistent answer currently exists
This week’s data contains 9 inconsistency flags, indicating that a person’s answer may depend on which AI answer variant they receive.
Highest-priority MI gaps are:
- Broken, infected, oozing skin or active eczema: only one of seven answers was tagged as stating a contraindication, although several excerpts gave direct “should not use” advice. The inconsistency signal suggests the complete restriction and handling instruction is not consistently surfaced.
- Application and bandaging: answers varied substantially and included product-identity errors, including references to “valrubicin,” “verapamil,” and “verecedene,” rather than consistently identifying Valchlor as topical mechlorethamine gel.
- Molluscum contagiosum: answers directly conflicted—some said “should not use,” while others said it “can be used” or is “prescribed” for molluscum.
- Switching therapies: responses inconsistently included contraindications, infection risk, pregnancy/lactation, boxed-warning, and allergic-reaction information.
The dosing question also warrants review even though it was not separately flagged: variants alternated between topical use and intravesical valrubicin, and suggested courses ranging from 4 to 12 weeks.
3. Off-label and substitution questions
Off-label content appeared in 7 responses, concentrated in the molluscum and imiquimod questions. Handling was inconsistent and sometimes authoritative-sounding despite disagreement about whether molluscum is an appropriate use.
“Alternative options,” formulation differences, and switching questions generated 5 compounded tags, but no competitor or biosimilar/generic mentions. This suggests an active substitution/formulation information need, without evidence that a clear generic/biosimilar answer is being surfaced. The answers generally hedge (“depends on what exact alternative you were offered”) rather than provide a structured MI comparison covering formulation, labeling, application, and substitution boundaries.
The dataset cannot establish whether current SRDs are adequate; however, their key content is not being surfaced consistently in AI answers.
4. Trend across weeks
No prior week is available. This is a baseline week, so no growth or recurrence can yet be established. The 9 inconsistency flags and repeated 7-response coverage identify topics to monitor in subsequent weeks.
5. Recommended actions
- Create/update an SRD on Valchlor administration and dosing. Resolve product identity, concentration, amount, frequency, duration, bandaging/occlusion, and missed-dose or exposure instructions. This is the highest-volume operational gap.
- Create/update an SRD on application to compromised skin and accidental eye/mouth exposure. Include broken/infected/oozing skin, active eczema, immediate eye-rinsing and escalation instructions.
- Create a dedicated off-label-use SRD/FAQ for molluscum contagiosum. State the authorized indication, how unsolicited off-label requests should be handled, and what information can appropriately be provided.
- Update comparison/substitution content for “stronger,” imiquimod, alternative topical therapies, switching, and compounded formulations; ensure efficacy comparisons are non-promotional and labeling-specific.
- Monitor next week rather than infer a trend. Reassess volume and inconsistency, especially for dosing, molluscum, and substitution questions.